Clostridium News and Research

RSS

Scientists determine 500 three-dimensional protein structures from bacterial and protozoan pathogens

9 Dec 2010

Journal of Hand Surgery publishes XIAFLEX CORD II phase III clinical trial

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that The Journal of Hand Surgery (JHS) has published in its December 2010 online edition pivotal CORD II phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class biologic, conducted by BioSpecifics' strategic partner Auxilium Pharmaceuticals Inc., for the nonsurgical treatment of adult Dupuytren's contracture patients with a palpable cord.

8 Dec 2010

Scientists work together to wipe out some of the most lethal diseases

Scientists at Seattle Biomedical Research Institute and Northwestern University Feinberg School of Medicine have reached a major milestone in the effort to wipe out some of the most lethal diseases on the planet. As leaders of two large structural genomics centers, they've experimentally determined 500 three-dimensional protein structures from a number of bacterial and protozoan pathogens, which could potentially lead to new drugs, vaccines and diagnostics to combat deadly infectious diseases.

8 Dec 2010

Researchers synthesize wound-healing peptides

Newly-created bioactive peptides promote wound healing through the growth of new blood vessels and epithelial tissue, such as skin. These wound-healing peptides, synthesized by researchers at the Tufts Center for Innovations in Wound Healing Research, increased angiogenesis in vitro by 200 percent.

8 Dec 2010

Study raises questions about therapeutic use of botulinum toxin A

A new study by researchers at the Faculty of Kinesiology, University of Calgary, is raising questions about the therapeutic use of botulinum toxin A.

3 Dec 2010

Sanofi Pasteur commences phase II clinical study of vaccine for Clostridium difficile infection prevention

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has started its phase II clinical study of a vaccine for primary prevention of Clostridium difficile infection (CDI). The trial starting in the United States is focused on evaluating prevention of the first episode of CDI in at-risk individuals, which includes adults with imminent hospitalization or current or impending residence in a long-term care or rehabilitation facility.

30 Nov 2010

National campaign to highlight significance of antibiotic resistance

Antibiotic resistance is one of the world's most pressing public health threats. To bring attention to this increasing problem, the Centers for Disease Control and Prevention and other government partners will observe its third annual Get Smart About Antibiotics Week on Nov. 15-21, 2010.

16 Nov 2010

Novel light technology kills hospital superbugs

A pioneering lighting system that can kill hospital superbugs - including MRSA and C.diff - has been developed by researchers at the University of Strathclyde in Glasgow. Scotland.

15 Nov 2010

PenCLAHRC provides funding to support C. difficile research

The Peninsula Collaboration for Leadership in Applied Health Research and Care (PenCLAHRC) has provided funding to support joint research between the University of Exeter and the Royal Devon & Exeter NHS Foundation Trust to investigate why some cases of Clostridium difficile infection (CDI) are more difficult to treat than others and also why some cases result in more incidences of relapses.

12 Nov 2010

PPH uses Xenex PX-UV disinfection system to destroy microorganisms causing HAIs

Palomar Pomerado Health (PPH) today announced it is the first health system in California to use the Xenex PX-UV disinfection system in its patient and operating rooms. The Xenex system is the fastest, safest and most cost-effective method for the advanced cleaning of hospital rooms in the world today, scientifically proven to destroy all major classes of microorganisms that cause hospital acquired infections (HAIs), such as MRSA and Clostridium difficile (C. diff).

11 Nov 2010

Intercell aggregate revenues decrease 28.4% to EUR 21.1m in 9 months ended September 30, 2010

Today, Intercell AG announced its financial results for the third quarter of 2010 and presented an update on the Company's key R&D programs as well as changes to the Management Board.

9 Nov 2010

Merz to present data on Xeomin clinical studies for cervical dystonia at AAPM&R

Merz Pharmaceuticals announced today that data from stability and clinical studies evaluating Xeomin (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, will be presented at the 71st Annual Assembly of the American Academy of Physical Medicine and Rehabilitation (AAPM&R) in Seattle, Wash.

8 Nov 2010

Optimer third quarter net loss increases to $11.8 million

Optimer Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2010. Optimer reported a net loss for the third quarter of 2010 of $11.8 million, or $0.30 per share, which was in line with the Company's expectations. This compares to a net loss for the third quarter of 2009 of $9.4 million, or $0.28 per share. The increase in net loss was primarily due to an increase in research and development and marketing expenses.

2 Nov 2010

H. pylori infection reduces severity of Salmonella-induced colitis: Research

Helicobacter pylori, a common stomach bacterium, reduced the severity of inflammation of the colon caused by Salmonella in mice, according to research from U-M Medical School scientists.

2 Nov 2010

University of Padua Professor wins Paul Ehrlich and Ludwig Darmstaedter Prize

Frankfurt am Main. The chemist and biologist Professor Cesare Montecucco, 62, of the Department of Biomedical Research at the University of Padua, Italy, has won the 100,000 euro Paul Ehrlich and Ludwig Darmstaedter Prize 2011 for his contribution to research in the field of bacterial diseases, including tetanus, botulism, anthrax and Helicobacter pylori associated diseases.

27 Oct 2010

Optimer presents two fidaxomicin Phase 3 trials data for CDI infection at IDSA Annual Meeting

Optimer Pharmaceuticals, Inc. announced today the presentation of combined data from its two fidaxomicin Phase 3 trials in patients with Clostridium difficile infection (CDI) at the 48th Annual Meeting of the Infectious Disease Society of America (IDSA) in Vancouver, British Columbia, Canada.

25 Oct 2010

ACG 75th Scientific Meeting to review advances in gastrointestinal research, treatment of digestive diseases

Many of the world's preeminent gastroenterologists will gather for the American College of Gastroenterology's (ACG) 75th Annual Scientific Meeting at the Henry B. Gonzalez Convention Center in San Antonio, Texas starting Monday October 18, 2010, to review the latest scientific advances in gastrointestinal research, treatment of digestive diseases and clinical practice management.

19 Oct 2010

Researchers explore impact of various factors on increasing rates of Clostridium difficile infection

In five different studies presented at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, researchers explored the impact of various factors on increasing rates of Clostridium difficile infection (C. difficile), such as the use of proton pump inhibitors (PPIs) and the substantial increase in antibiotic use due to new National Hospital Quality Measures; strategies to combat high rates of C. difficile infections; and cutting‐edge treatments for this potentially deadly-and quite common-infection.

19 Oct 2010

Cubist third quarter total net revenues increase 13% to $162.1M

Cubist Pharmaceuticals, Inc. today announced results for the third quarter ended September 30, 2010.

15 Oct 2010

Auxilium receives USPTO patent for XIAFLEX product

Auxilium Pharmaceuticals, Inc. a specialty biopharmaceutical company, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 7,811,560 claiming, among other things, purified collagenase, the active component in Auxilium's product XIAFLEX (collagenase clostridium histolyticum).

13 Oct 2010